Clinical Trial Update: Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating thalidomide in relapsed or refractory non-Hodgkin lymphoma has completed enrollment. The study included patients with recurrent grade 1…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Non-hodgkin Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• Thalidomide (thalidomide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma | Phase 2 | Status: COMPLETED